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http://www.biomedcentral.com/1472-684X/13/14RESEARCH ARTICLE Open AccessOxidative stress level is not associated with
survival in terminally ill cancer patients:
a preliminary study
Chang Hwan Yeom1†, Youn Seon Choi2†, Hong Yup Ahn3, Su Hey Lee2 and In Cheol Hwang4*Abstract
Background: While cancer patients have higher oxidative stress (OS) and lower antioxidant activity, evidence for
the association of these parameters with survival in patients with terminally ill cancer is lacking.
Methods: We followed 65 terminal cancer patients prospectively. We assessed their performance status, some
symptoms, and serum levels of vitamin C and OS level. The Gehan’s generalized Wilcoxon test was used to
examine the association between survival times and variables.
Results: Subjects’ performance status was very poor and they had a high level of OS and a low level of vitamin C.
No significant association of these two parameters with survival time was noted (p-value, 0.637 for high OS and
0.240 for low vitamin C). Poor performance status was independently related to high OS status after adjusting for
potential confounders (adjusted OR, 4.45; p-value, 0.031).
Conclusions: In this study, OS was not associated with survival of terminally ill cancer patients and its prognostic
role requires further study.Background
Prognostication of life expectancy is a significant clinical
commitment for clinicians involved in oncology, espe-
cially in hospice-palliative care settings. Accurate esti-
mates provide patients and families with a time frame in
which to emotionally and financially prepare for the
death [1]. However, studies on survival prediction in ter-
minally ill patients suggest that it is very difficult to
make an accurate prognosis and even experienced pallia-
tive care physicians find such a prediction difficult [2].
Patients with malignant tumors have higher oxidative
stress (OS) by tumor growth itself and/or increased sys-
temic inflammatory response [3,4]. OS is defined as a state
in which the level of toxic reactive oxygen intermediates
overcomes the endogenous antioxidant defenses. OS can
therefore result from either excess production of free radi-
cals or depletion of antioxidant defenses [5]. Meanwhile,* Correspondence: spfe0211@gmail.com
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unless otherwise stated.vitamin C is a well-known antioxidant that humans are
unable to synthesize and must obtain from an ex-
ogenous source. Reductions in vitamin C intake are asso-
ciated with illness, hospitalization, and institutionalization.
A population-based cohort study with breast cancer pa-
tients demonstrated that women consuming the highest
tertile of vitamin C were significantly more likely to sur-
vive compared to those in the lowest tertile of intake [6].
Furthermore, a recent study reported that patients with
low plasma levels of vitamin C have a significantly worse
prognosis than patients with normal levels [7].
While a few studies have shown a correlation between
survival and either serum vitamin C level or OS in can-
cer patients, direct evidence for this association in ter-
minally ill cancer patients is lacking. Therefore, we
aimed primarily to determine the relationship between
survival and serum vitamin C or OS level in terminally-
ill cancer patients. In addition, even if not associated
with survival, we investigated whether these specific la-
boratory findings were connected with performance sta-
tus (PS).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Design and subjects
This prospective observational study was carried out at
two hospice-palliative care units. From January 2012 to
June 2012, we identified 296 consecutive terminally ill
cancer patients who were admitted to facilities. A terminal
cancer patient was defined as someone with progressive
advanced cancer for whom conventional anticancer ther-
apy was no longer indicated [1]. No subject included in
the study had taken a vitamin supplement during the two
days before enrollment, had received a blood transfusion
or albumin during the one week before enrollment, had a
chronic kidney disease, or had a hematologic malignancy.
In addition, physicians determined eligibility for participa-
tion based on their capacity to communicate and to
understand the aim of the study. Data of 65 patients were
analyzed finally and a flowchart of patient recruitment
depicted in Figure 1. This study was conducted in ac-
cordance with the Declaration of Helsinki. Written in-
formed consent was obtained from each subject. The
study was approved by Local Research Ethical Committee
of Gachon University Gil Hospital (GIRBA2614) and the
Korea University Guro Hospital (MD11033).
Clinical examination
Data on demographics and clinical information were col-
lected by an experienced palliative care team of physicians
and registered nurses: included information were age, sex,
cancer site, Eastern Cooperative Oncology Group (ECOG)
performance status, palliative prognostic score [8], pres-
ence of fever and anorexia, and evidence of infection. The
ECOG performance status is an observer-rated scale of
patient physical ability using numbers ranging from 0
(able to carry out all normal activities) to 4 (completely
disabled) [9]. Anorexia was defined as less than five
spoons per meal (about one-third amount of routine
meal). Patients also provided clinical information on
average pain score by numerical rating scale and presenceAdmitted pa
Eligible
(n = 143, 48.3%)
(
Ineligible                                (n = 78, 54.5%)
Incapacitateda (n = 62)
Refuse to participate (n = 16)
Alive at the end of stud
(n = 16, 24.6%)
Figure 1 Flowchart of patient recruitment. aphysician-assessed.of some symptoms (dysphagia and dyspnea on exer-
tion). Dysphagia and dyspnea were determined by the
following yes-no question: “In the past 24 h, have you
been difficult to swallow/short of breath on exertion?”
Survival times were measured from the date of enroll-
ment in the study.
Blood assays
In all subjects, blood samples were obtained from
venipuncture of an antecubital vein. Blood samples were
used to measure complete blood cell count (white blood
cell and lymphocyte proportion), liver function (albumin
and total bilirubin), uric acid, creatinine, lactate de-
hydrogenase (LDH) and C-reactive protein (CRP). We
determined oxidative stress levels by the Free Oxygen
Radical Test (FORT; Free Oxygen Radicals Monitor Plus,
Callegari, Italy), a colorimetric assay based on the ability
of transition metals, such as iron, to catalyze the break-
down of hydroperoxides (ROOH) into derivative radicals,
according to Fenton’s reaction. Results are expressed as
FORT units (U.F.), where 1 U.F. corresponds to 0.26 mg/l
H2O2. The assay is completed in 6 minutes. Data suggest
that FORT can satisfactorily assess the level of oxidative
radicals in whole blood [10]. We also measured serum
vitamin C concentration by High Performance Liquid
Chromatography, which has been validated as a rapid an
specific measurement of vitamin C [11].
Statistical analysis
Data are presented as median (interquartile range) or
number (%). We dichotomized variables and chose a
cut-off point at the reference range or median values. To
examine the association between survival times and vari-
ables, and we used Gehan’s generalized Wilcoxon test. We
evaluated the associations between OS and PS using the
logistic regression model. We used SPSS statistical pack-
age version 16.02 (SPSS, Chicago, IL, USA). P values less
than 0.05 were considered significant.tients with terminal cancer
(n = 296)
Ineligible (n = 153, 51.7%)
Transfusion (n = 124)
Chronic kidney disease                (n = 13)
Hematologic malignancy (n = 12)
Vitamin supplement (n = 4)
Final patients
n = 65, 45.5%)
y Deceased at the end of study 
(n = 49, 75.4%)
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Patient population and clinical characteristics
The demographic and clinical characteristics of the
patients included in this study are shown in Table 1.
In brief, most of the patients were between 58 and
76 years old and there were similar proportions by gender
(male, 52.3%). Nearly half of the patients had lung orTable 1 Characteristics of study patients (N = 65)
n (%)
Agea, years 66 (58–76)















Current infection 29 (44.6)
Anorexia 59 (90.8)
Dysphagia 24 (36.9)
Dyspnea on exertion 15 (23.1)





Laboratory findingsa (reference range)
Bilirubin, mg/dL (0.2-1.2) 0.6 (0.3-1.2)
Creatinine, mg/dL (0.5-1.2) 0.6 (0.4-0.9)
Lactate dehydrogenase, U/L (200–485) 557 (427–776)
Uric acid, mg/dL (2.5-8.3) 3.7 (2.6-6.0)
Albumin, g/dL (3.5-5.2) 3.0 (2.6-3.3)
C-reactive protein, mg/dL (< 0.5) 16.3 (4.0-74.5)
Vitamin C, μg/mL (1.9-15.0) 0.44 (< 0.03-0.89)
Oxidative stressc, U.F. (160–310) 412.9 (305.1-539.2)
Abbreviations: ECOG Eastern Cooperative Oncology Group, NRS numerical
rating score.
aExpressed as median (interquartile range).
bExpressed as median (95% CI).
cBy Free Oxygen Radical Test.gastrointestinal tract cancer (44.6%). As would be ex-
pected in hospice-palliative care units, the PS of the sub-
jects was poor: 96.9% of patients were ECOG 3 or 4.
Median survival was 19 days (95% CI, 11–32 days). The
median values of LDH, albumin, vitamin C and OS were
outside their reference range.
Prognostic factors on survival
In univariate survival analysis, male gender (HR, 1.95;
P = 0.024), poor PS (HR, 1.91; P = 0.032), higher pal-
liative prognostic score (HR, 2.30; P < 0.01), and elevated
serum creatinine levels (HR, 4.22; P < 0.01) were signifi-
cant predictors of decreased survival time (Table 2). No
significant influences of OS or vitamin C level on survival
time were noted (P = 0.24 for vitamin C and P = 0.637 for
OS, respectively).
OS and PS
Table 3 lists the associated factors with high OS level.
Subjects with poor PS (ECOG= 4) had significantly higher
proportion with high OS level (OR, 3.61; P = 0.025). This
relationship remained robust after adjusting for potential
confounders, such as age group, sex, presence of fever and
hypoalbuminemia (OR, 4.45; P = 0.031).
Discussion
The idea of being able to prognosticate from the results
of a simple blood test is very appealing to palliative care
physicians. The need for a blood sample must also be
weighed against the likely clinical advantage for the indi-
vidual patient. Biologic parameters have not been as
widely investigated as clinical parameters in terminally
ill cancer patients [12], and a more accurate evaluation
of these variables in relation to prognosis is undoubtedly
warranted.
To our knowledge, this is a rare study that investigated
the clinical effectiveness of measuring serum vitamin C
or OS in terminally ill cancer patients. In this study, the
main findings were that: (i) these parameters had no
prognostic significance; (ii) serum OS level was associ-
ated with PS of patients; and (iii) serum vitamin C level
was not correlated with OS level.
It is well known that cancer patients are characterized
by higher levels of OS markers and lower levels of serum
vitamin C than healthy controls; there is a scarcity of lit-
erature addressing the association with survival of ad-
vanced cancer patients at the end of life [13]. Mayland
et al. [7] reported that low plasma vitamin C concentra-
tions were associated with shorter survival in terminally
ill cancer patients. But those findings were not con-
firmed by multivariate analysis and they did not address
the level of OS, which could be a predictor of cancer-
specific survival [14]. In the current study, we were un-
able to demonstrate prognostic significance of serum
Table 2 Patient characteristics and univariate survival analysis
No. of patients MST (days) HR (95% CI) P Valueb
Age (years)
≤ 65 32 23 1
> 65 33 11 1.19 (0.68-2.09) 0.544
Sex
Female 31 31 1
Male 34 11 1.95 (1.09-3.50) 0.024
Primary tumor site (any type)
Lung 16 32 0.71 (0.37-1.36) 0.300
Gastrointestinal 13 14 1.34 (0.68-2.66) 0.401
Pancreas 11 17 1.38 (0.67-2.86) 0.387
Hepatobiliary 10 10 1.39 (0.65-3.00) 0.396
Others 15 19 0.70 (0.34-1.45) 0.332
ECOG PS
2-3 44 23 1
4 21 10 1.91 (1.06-3.45) 0.032
Palliative prognostic score
< 7.5a 31 22 1
≥ 7.5a 34 10 2.30 (1.27-4.17) < 0.01
Laboratory variables
Bilirubin (mg/dL)
WNR 47 22 1
Hyperbilirubinemia 18 11 1.45 (0.79-2.69) 0.233
Creatinine (mg/dL)
WNR 56 22 1
Elevated 9 6 4.22 (1.98-9.02) < 0.01
Lactate dehydrogenase (U/L)
WNR 19 31 1
Elevated 41 15 1.25 (0.65-2.42) 0.500
Uric acid (mg/dL)
WNR 54 22 1
Hyperuricemia 8 12 2.10 (0.92-4.82) 0.078
Albumin (g/dL)
WNR 11 31 1
Hypoalbuminemia 54 17 1.52 (0.68-3.39) 0.311
C-reactive protein (mg/dL)
< 16.3a 33 18 1
≥ 16.3a 32 19 0.60 (0.33-1.07) 0.084
Serum vitamin C (μg/mL)
≥ 0.44a 33 17 1
< 0.44a 32 20 0.71 (0.40-1.26) 0.240
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Table 2 Patient characteristics and univariate survival analysis (Continued)
Oxidative stress (U.F.)
< 412.9a 32 22 1
≥ 412.9a 33 15 1.15 (0.65-2.02) 0.637
Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status, WNR within normal range, MST median survival time, HR hazard ratio,
CI confidence interval.
aMedian value.
bGehan’s generalized Wilcoxon method.
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could be due to (i) true negative finding: these parame-
ters are not helpful to discriminate the patients with a
short survival, or (ii) false negative findings: small sam-
ple size or artificial cutoff value.
While several studies have shown that OS level was as-
sociated with the cancer patient’s PS [15,16], little work
has been done in terminally ill cancer patients. The dis-
tressing symptoms experienced by cancer patients may
be related to OS: these symptoms may also lead to the
patients’ poor PS [17]. Especially in the terminal stage, de-
ranged energy metabolism, which may account for symp-
toms such as nausea/vomiting, anorexia and cachexia that
cause malnutrition, could accelerate the production of freeTable 3 Oxidative stress status and baseline clinical character
Higher oxidativ
OR
Aged (> 65 yrs) 1.06
Sex (male) 1.98






Dyspnea on exertion 1.63




Elevated lactate dehydrogenase 1.64
Hyperuricemia 0.77
Hypoalbuminemia 0.18
Higha C-reactive protein 1.54
Lowa vitamin C 0.74
Performance (ECOG = 4)
Unadjusted 3.61
Adjustedb 4.45
Abbreviations: NRS numerical rating score, ECOG Eastern Cooperative Oncology Gro
aBased on the median value.
bAdjusted for age group, sex, fever, and hypoalbuminemia.radicals. Additionally, a previous study reported that the
OS levels decreased significantly after antioxidant treat-
ment regardless of patient’s PS [15], although these reduc-
tions might not lead to performance improvement [17,18].
Further well-controlled clinical trials are needed to clarify
the clinical effect of intervention.
Based on the complex situation caused by an imbal-
ance between OS and antioxidant ability, it is plausible
that separate assessments of OS and antioxidant status
do not provide sufficient information [19]. For that rea-
son we assessed both parameters, but could not find any
correlation between them. With healthy adults, Block
et al. [20] found that serum vitamin C was inversely cor-
related with biomarkers of OS even after adjusting foristics
e stress (≥ median, 412.9 U.F.)
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OS constantly and prevents certain damage by scaven-
ging reactive oxygen species [21], but this balance may
be limited to healthy subjects. As the disease progresses
and death nears, OS levels escalate markedly without
linear reduction of antioxidant capacity. Therefore, a
higher OS level may have more influence on the outcome
for terminal cancer patients than decreased antioxidant
biomarkers. Two recent studies by Vera-Ramirez et al.
with breast cancer patients back this up. In non-metastatic
breast cancer patients, they demonstrated that both anti-
oxidant capacity and OS biomarkers had significant associ-
ation with survival rate [22]. In contrast, in a metastatic
setting with the same protocol, only OS parameters signifi-
cantly influenced the survival rates of the patients [14].
The current study contains some limitations that should
be acknowledged. First, this sample of patients is too
small. Large-scale studies are needed to confirm our find-
ings, because short survival time is unavoidable when
dealing with subjects in a hospice setting. Second, by using
a single measurement, we have likely underestimated the
association of serum vitamin C level and OS status with
survival. Third, we only adjusted for confounders statisti-
cally and could not exclude acute inflammatory conditions
or anti-inflammatory medication users, which can affect
OS [23]. However, terminally ill cancer patients are very
susceptible to infection [24], and they have also taken
multiple drugs due to a wide variety of symptoms and as-
sociated comorbid conditions [25]. Finally, some symp-
toms such as anorexia, dysphagia and dyspea on exertion
were not evaluated by a validated symptom assessment
tool.
Conclusions
Our study demonstrates that OS status was not associ-
ated with survival of cancer patients at the very end of
life. Further studies are needed in order to elucidate the
relationship between survival and OS.
Competing interests
CHY is the chairperson of the Korean Association for Vitamin Research. All
authors have no potential conflicts of interest concerning this article.
Authors’ contributions
CHY, YSC, and ICH designed study. CHY, YSC and ICH wrote the manuscript.
YSC, SHL and ICH conducted study and collected the data. AHY and ICH
analysed the data. CHY, YSC and ICH interpreted the data. All authors read
and approved the final manuscript.
Acknowledgements
This study was supported by the Korean Association for Vitamin Research.
The sponsor had no role in this study.
Author details
1Ucell clinic, Seoul, Republic of Korea. 2Department of Family Medicine, Korea
University Guro Hospital, Seoul, Republic of Korea. 3Department of Statistics,
Dongguk University, Seoul, Republic of Korea. 4Palliative Care Unit, Division
of Cancer Control & Prevention, Incheon Regional Cancer Center, 1198
Guwol-dong, Namdong-gu, Incheon 405-760, Republic of Korea.Received: 30 November 2013 Accepted: 19 March 2014
Published: 21 March 2014References
1. Yun YH, Heo DS, Heo BY, Yoo TW, Bae JM, Ahn SH: Development of
terminal cancer prognostic score as an index in terminally ill cancer
patients. Oncol Rep 2001, 8(4):795–800.
2. Glare PA, Sinclair CT: Palliative medicine review: prognostication. J Palliat
Med 2008, 11(1):84–103.
3. Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in
cancer. FEBS Lett 1995, 358(1):1–3.
4. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress,
inflammation, and cancer: how are they linked? Free Radic Biol Med 2010,
49(11):1603–1616.
5. McCall MR, Frei B: Can antioxidant vitamins materially reduce oxidative
damage in humans? Free Radic Biol Med 1999, 26(7–8):1034–1053.
6. McEligot AJ, Largent J, Ziogas A, Peel D, Anton-Culver H: Dietary fat, fiber,
vegetable, and micronutrients are associated with overall survival in
postmenopausal women diagnosed with breast cancer. Nutr Cancer 2006,
55(2):132–140.
7. Mayland CR, Bennett MI, Allan K: Vitamin C deficiency in cancer patients.
Palliat Med 2005, 19(1):17–20.
8. Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G, Petrella
V, Barni S, Zecca E, Scarpi E, Labianca R, Amadori D, Luporini G: A new
palliative prognostic score: a first step for the staging of terminally ill
cancer patients. Italian Multicenter and Study Group on Palliative Care.
J Pain Symptom Manage 1999, 17(4):231–239.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET,
Carbone PP: Toxicity and response criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 1982, 5(6):649–655.
10. Palmieri B, Sblendorio V: Current status of measuring oxidative stress.
Methods Mol Biol 2010, 594:3–17.
11. Tessier F, Birlouez-Aragon I, Tjani C, Guilland JC: Validation of a micromethod
for determining oxidized and reduced vitamin C in plasma by
HPLC-fluorescence. Int J Vitam Nutr Res 1996, 66(2):166–170.
12. Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME: Survival
prediction in terminal cancer patients: a systematic review of the
medical literature. Palliat Med 2000, 14(5):363–374.
13. Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M,
Pourmoghaddam M: Evaluation of oxidative stress, antioxidant status
and serum vitamin C levels in cancer patients. Biol Trace Elem Res
2009, 130(1):1–6.
14. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL,
Granados-Principal S, Lorente JA, Quiles JL: Oxidative stress status in
metastatic breast cancer patients receiving palliative chemotherapy
and its impact on survival rates. Free Radic Res 2012, 46(1):2–10.
15. Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso
MR, Murgia V, Camboni P, Ferreli L: Reactive oxygen species, antioxidant
mechanisms and serum cytokine levels in cancer patients: impact of an
antioxidant treatment. J Cell Mol Med 2002, 6(4):570–582.
16. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR,
Massa E, Mocci M, Serpe R: Antioxidant agents are effective in inducing
lymphocyte progression through cell cycle in advanced cancer patients:
assessment of the most important laboratory indexes of cachexia and
oxidative stress. J Mol Med (Berl) 2003, 81(10):664–673.
17. Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E,
Astara G, Serpe R: Cancer-related anorexia/cachexia syndrome and
oxidative stress: an innovative approach beyond current treatment.
Cancer Epidemiol Biomarkers Prev 2004, 13(10):1651–1659.
18. Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC,
Panzone F, Mantovani G: A randomized phase III clinical trial of a
combined treatment for cachexia in patients with gynecological cancers:
evaluating the impact on metabolic and inflammatory profiles and
quality of life. Gynecol Oncol 2012, 124(3):417–425.
19. Hristozov D, Gadjeva V, Vlaykova T, Dimitrov G: Evaluation of oxidative
stress in patients with cancer. Arch Physiol Biochem 2001,
109(4):331–336.
20. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L:
Factors associated with oxidative stress in human populations. Am J
Epidemiol 2002, 156(3):274–285.
Yeom et al. BMC Palliative Care 2014, 13:14 Page 7 of 7
http://www.biomedcentral.com/1472-684X/13/1421. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals
and antioxidants in oxidative stress-induced cancer. Chem Biol Interact
2006, 160(1):1–40.
22. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL,
Granados-Principal S, Fernandez-Navarro M, Lorente JA, Quiles JL: Does
chemotherapy-induced oxidative stress improve the survival rates of
breast cancer patients? Antioxid Redox Signal 2011, 15(4):903–909.
23. Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, Cawich I,
Sawamura T, Kavdia M, Mehta JL: Modulation of ADP-induced platelet
activation by aspirin and pravastatin: role of lectin-like oxidized
low-density lipoprotein receptor-1, nitric oxide, oxidative stress,
and inside-out integrin signaling. J Pharmacol Exp Ther 2007,
322(3):1324–1332.
24. Chanock S: Evolving risk factors for infectious complications of cancer
therapy. Hematol Oncol Clin North Am 1993, 7(4):771–793.
25. McLean S, Sheehy-Skeffington B, O’Leary N, O’Gorman A: Pharmacological
management of co-morbid conditions at the end of life: is less more? Ir J
Med Sci 2013, 182(1):107–112.
doi:10.1186/1472-684X-13-14
Cite this article as: Yeom et al.: Oxidative stress level is not associated
with survival in terminally ill cancer patients: a preliminary study.
BMC Palliative Care 2014 13:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
